Results 151 to 160 of about 3,191,959 (309)

Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer.

Breast cancer includes several subtypes with distinct characteristic biological, pathologic, and clinical features. Elucidating subtype-specific genetic etiology could provide insights into the heterogeneity of breast cancer to facilitate the development
Knight, JA, John, EM, Hu, JJ, Buas, MF, Reiner, AS, Cai, Q, Pal, T, Jia, G, Derkach, A, Chen, Y, Ambrosone, CB, Olopade, OI, Chen, J, Press, MF, Shu, X, Gu, J, Ping, J, Sandler, DP, Zheng, W, Haiman, CA, Offit, K, Wang, X, Nemesure, B, Troester, MA, Palmer, JR, Guo, X, Nathanson, KL, Garcia-Closas, M, Shu, X-O, Woods, M, Yang, Y, Watt, GP, Sanderson, M, Liang, X, Ambs, S, Concannon, P, Verma, SP, Huo, D, Bernstein, JL, Oh, JH, Lynch, CF, Olshan, AF, Long, J, Li, CI, Sun, X, Mellemkjær, L   +45 more
core   +1 more source

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.

, 2019
It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction.
Minchom, AR, Pölsterl, S, Banerji, U, Coker, EA, Al-Lazikani, B, Cunningham, D, Raynaud, FI, Stewart, A, Carreira, S, Georgiou, A, O'Brien, ME, de Bono, JS   +11 more
core   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

Editorial: Cholesterol and cancer drug resistance: Molecular, signaling, and therapeutic aspects

Frontiers in Genetics, 2022
Mandeep Kaur, Mandeep Kaur, Zodwa Dlamini   +2 more
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

A pan-cancer cuproptosis signature predicting immunotherapy response and prognosis

Heliyon
Background: Cuproptosis may represent a potential biomarker for predicting prognosis and immunotherapy response, but the available evidence is insufficient.
Xiaojing Zhu, Zixin Zhang, Yanqi Xiao, Hao Wang, Jiaxing Zhang, Mingwei Wang, Minghui Jiang, Yan Xu   +7 more
doaj   +1 more source

Tetrastigma Hemsleyanum Polysaccharide Suppresses Triple‐Negative Breast Cancer by Disrupting the Hippo‐YAP/TEAD4‐PDIA4 Axis and Endoplasmic Reticulum Stress Adaptation

Advanced Science, EarlyView.
ABSTRACT Triple‐negative breast cancer (TNBC) exhibits addiction to chronic endoplasmic reticulum (ER) stress, which sustains an aggressive metastatic phenotype through activation of the unfolded protein response (UPR). Here, we identify a previously unrecognized “ER‐stress addiction” axis in which the Hippo pathway effector TEAD4 directly ...
Yini Shang, Wentao Si, Youxue Zhang, Jialin Liu, Huaixi Zhang, Yafei Li, Hongmeng Su, Wei Jiang, Zhishan Ding, Lihong Wang   +9 more
wiley   +1 more source

Machine learning for prediction of 30-day mortality in patients with advanced cancer: comparing pan-cancer and single-cancer models

ESMO Real World Data and Digital Oncology
Background: Systemic anticancer therapy (SACT) near the end of life (EOL) reduces the quality of the patient’s remaining life without clinical benefit.
S. Bjerregaard-Michelsen, L.Ø. Poulsen, A. Bjerrum, M. Bøgsted, C. Vesteghem   +4 more
doaj   +1 more source

Cancer Research UK Cancer Awareness Measures, February 2023

, 2023
copyright UK Data Service and data collection copyright owner.The Cancer Awareness Measure (CAM) was developed in 2007-8 to address the absence of a validated measure of general public awareness of cancer (Stubbings, S., Robb, K., Waller, J., Ramirez, A.,
Cancer Research UK
core  

Combating VEGFA‐siRNA‐Induced Metabolic Reprogramming via Glucose Utilization Deprivation

Advanced Science, EarlyView.
An ionizable lipid nanoparticle co‐delivers VEGFA siRNA and glucose oxidase to tumors to counteract VEGFA knockdown‐induced, glutamine‐driven metabolic compensation. Enzymatic glucose consumption reverses the adaptive pathways and restores metabolism toward baseline, thereby sensitizing tumors to therapy.
Lulu Zheng, Shuai Guo, Yingjixing Luo, Pengfei Wu, Haiyin Yang, Yingqiu Xie, Yuchuan Fan, Qing Liu, Bo Hu, Jia Huang, Yuanyu Huang   +10 more
wiley   +1 more source